Vimab Group Past Earnings Performance
Past criteria checks 0/6
Vimab Group has been growing earnings at an average annual rate of 40%, while the Professional Services industry saw earnings growing at 15.1% annually. Revenues have been growing at an average rate of 14.3% per year.
Key information
40.0%
Earnings growth rate
94.1%
EPS growth rate
| Professional Services Industry Growth | 14.5% |
| Revenue growth rate | 14.3% |
| Return on equity | -7.4% |
| Net Margin | -1.2% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Vimab Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 342 | -4 | 84 | 0 |
| 30 Sep 23 | 295 | -14 | 77 | 0 |
| 30 Jun 23 | 255 | -26 | 63 | 0 |
| 31 Mar 23 | 237 | -27 | 61 | 0 |
| 31 Dec 22 | 227 | -34 | 57 | 0 |
| 30 Sep 22 | 211 | -28 | 55 | 0 |
| 31 Dec 21 | 206 | -24 | 56 | 0 |
| 31 Dec 20 | 217 | -46 | 45 | 0 |
Quality Earnings: NM4 is currently unprofitable.
Growing Profit Margin: NM4 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if NM4's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare NM4's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NM4 is unprofitable, making it difficult to compare its past year earnings growth to the Professional Services industry (455.9%).
Return on Equity
High ROE: NM4 has a negative Return on Equity (-7.41%), as it is currently unprofitable.